29 April 2020
Visiongain has launched a new pharma report 3D Medical Imaging Devices Market Report 2020-2030: Forecasts by Device type (X-Ray Devices, CT Devices, Ultrasound Systems, MRI Equipment), Application (Oncology, Cardiology, Orthopedic), Solution (3D Rendering, 3D Scanning, 3D Modelling), and Geography (North America, Latin America, Europe, Asia Pacific, MEA).
Visiongain anticipates that the global 3D medical imaging devices market will witness a CAGR of xyz% over the forecast period from 2020 to 2030 and will surpass US $xyz billion by 2020. The market growth is attributed to the emergence of automated 3D imaging sensors coupled with growing technological advancements across the medical imaging sector.
To access the data contained in this document please email email@example.com
3D medical imaging devices comprise technologies involving various imaging modalities with the capability to diagnose and treat several diseases. Magnetic resonance imaging (MRI), ultrasound, tomography, and radiography are some of the systems associated with 3D medical imaging devices. According to Visiongain, the growing adoption of automated technologies, and enhancement in visualization techniques across the healthcare industry is anticipated to fuel market growth over the forecast period.
In recent years the healthcare industry has witnessed a whirlwind of change. These changes range from new policies, legislation to new use cases, and technology innovations. The market for diagnostic imaging technology is still witnessing several trends, which are a move towards patient-centered radiology and value-based imaging.
The advancements in the 3D medical imaging sector have come a long way from using computed tomography (CT scanners) & mammography devices to innovative technology for improved patient care. AI is also proving its worth as it automates routine procedures, provides faster diagnostic image processing, and allows healthcare staff to prioritize and respond more efficiently to the most demanding and critically ill patients. Yet medical imaging is one of today's most common and overused diagnostic techniques and by far the most expensive.
North America holds the majority of market share followed by Europe and will continue to hold significant market share in the future owing to the presence of established healthcare infrastructure and high purchasing power of healthcare setting e.g. hospitals, long term care settings, etc. Also, a growing number of research projects in the region, coupled with funding for research institutes from the government is anticipated to augur market growth. Also, the market will continue to be driven by the existence of the target population and increased R&D investment by important business organizations. However, the Asia Pacific region is expected to experience the highest growth in terms of CAGR over the forecast period owing to the growing healthcare sector across emerging economies like India and China. Additionally, unmet needs of patients and untapped countries in this region have been attracting investments by global players and this is expected to boost the 3D medical imaging devices market growth over the forecast period.
Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations, and launching new products to strengthen their position in the global 3D medical imaging devices market. Companies are also expanding their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the 3D medical imaging devices market.
For instance, in October 2018, Siemens unveiled its MAGNETOM RT Pro edition for MAGNETOM Sola, a new version of its 1.5 Tesla MRI scanner at its 60th annual meeting in American Society for Radiation Oncology (ASTRO). The scanner includes in-built software and hardware and is designed to assist in radiation therapy treatments.
The comprehensive market report features companies such as Siemens Healthineers Inc., GE Healthcare Limited, Koninklijke Philips N.V., Esaote SpA, Canon Medical Systems Corporation, Shimadzu Corporation, Hitachi Medical Corporation, Analogic Corporation, Del Medical Systems Group, Inc., Digirad Corporation, HP Corporation, Panasonic Corporation, Lockheed Martin, Agilent Technologies, Philips, among other prominent players. Also the research study offers market estimation and forecast for the period ranging 2020-2030 for global markets such as North America, Latin America, Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Russia, India, Japan, China, Australia, ASEAN, GCC and South Africa.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.
26 November 2020
Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.
26 November 2020
Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.
25 November 2020
Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth